{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-019531","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2025-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.584384+00:00","generated_at":"2026-05-25T19:05:06.560323+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BioXcel: FDA inspection closed with VAI; SERENITY trial enrolling; Nasdaq compliance regained; CMO resigns","bullets":["FDA closed TRANQUILITY II site inspection with 'Voluntary Action Indicated'; no regulatory action taken.","SERENITY At-Home Phase 3 trial: 23 sites open, enrolling; topline data expected H2 2025 for sNDA.","Regained compliance with Nasdaq minimum bid price rule; notice received Feb 28, 2025.","Vincent J. O'Neill, M.D. resigned as EVP, Chief of Product Development and Medical Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-019531","json":"https://secwatch.observer/filing/0001104659-25-019531.json","markdown":"https://secwatch.observer/filing/0001104659-25-019531.md","text":"https://secwatch.observer/filing/0001104659-25-019531.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925019531/0001104659-25-019531-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925019531/tm258055d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T19:05:06.560323+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}